A clinical study is happening across the US to explore an investigational treatment option for patients who experience prolonged life-threatening seizures.

Based on SE duration and response to treatment, it is divided into four stages: early, established, refractory and super-refractory status epilepticus. For this clinical study, the RESET study, investigators are looking at the second stage of SE, established status epilepticus (ESE), which is defined as SE that persists despite the first-line treatment (usually with benzodiazepine). Based on a variety of factors such as cause, age, and duration of the seizure, approximately 3% – 26% of patients with SE do not survive. Since longer seizures lead to greater risk of injury and death, it is important to treat patients experiencing SE as quickly as possible to try to stop the seizures.